The European Medicines Agency committee reports its November findings, including five drugs recommended for marketing authorisation.
List view / Grid view
Esmya (ulipristal acetate)
Filter the results
The EMA's PRAC has recommended the revocation of the marketing authorisation for ulipristal acetate, after a review confirmed liver injury caused by the medicine.